RET and thyroid cancer, nonmedullary, 2: At present, genetic tests including the combination of BRAF V600E and RAS point mutations and RET-PTC and PAX8-PPARγ rearrangements are considered to provide high specificity and positive predictive value for PTC and FTC diagnosis (“rule in” tests).